FilingSEC EDGAR6-K
Kamada Confirms Sufficient KedRAB® Supply to Meet Increased U.S. Demand
· SEC accepted
StageSupply Confirmation
Filing content
Following a CDC report on increased rabies exposures, Kamada confirmed it has sufficient inventory and manufacturing capacity to meet the rising demand for KedRAB® in the U.S.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…